期刊文献+

颗粒增强免疫比浊法测定血清同型半胱氨酸的方法学评价

Methodology evaluation of detecting serum homocyteine by particle enhanced immunoturbidimetric method ycteine
下载PDF
导出
摘要 目的:对胶乳颗粒免疫比浊法测定血清同型半胱氨酸(HCY)的方法学进行初步评价。方法:应用胶乳颗粒免疫比浊法测定HCY的精密度、标准曲线、干扰实验、稳定性实验、并与循环酶法测定血清HCY的结果进行相关性分析。结果:颗粒增强免疫比浊法测定HCY的精密度(批内CV为1.87%、0.75%,批间CV为2.29%、5.35%)较高;HCY浓度在0μmol/L~50μmol/L范围内线性良好;当抗坏血酸浓度1107mg/L、胆红素浓度445 umol/L、血红蛋白浓度6.7 g/L;甘油三酯浓度14.6 mmol/L、氨离子浓度75 umol/L时均未对测定结果产生干扰;试剂开瓶后稳定周期也可达到25天;颗粒增强免疫比浊法和循环酶法测定HCY相关性良好(y =0.9904x +0.0813,r=0.9981)。结论:颗粒增强免疫比浊法测定血清HCY具有较高的精密度,结果准确可靠,适合临床实验室推广。 Objective:To evaluate the detection of serum homocysteine ( HCY) with Particle Enhanced Immunoturbidimetric. Methods:The precision, calibration curve, Anti interference test,on-board stability studies,and the determination of serum HCY and enzymatic cycling assay results by correlation analysis.Results: The Particle Enhanced Immunoturbidimetric method revealed good precision ( CV 1.87%、0.75% , 2.29%、5.35%) .The linear range is0μmol/L~ 50μmol/L.The assay demonstrated less than 10% interference deviation in the presence of Vic-C(1107mg/L), bilirubin(445 umol/L), hemoglobin( 6.7 g/L),TG(14.6 mmol/L), ammoniumion(75 umol/L).samples can be stable after 25 days on-board stability.the Particle enhanced immunoturbidimetric method showed a good correlation with enzymatic cycling assay (y = 0.9904x +0.0813,r= 0.9981).Conclusions:The Particle enhanced immunoturbidimetric method is precise, reliable and suitable for determinations of serum HCY concentration in a clinical laboratory.
出处 《医学检验与临床》 2014年第2期35-37,共3页 Medical Laboratory Science and Clinics
关键词 颗粒增强免疫比浊法 同型半胱氨酸 心血管疾病 方法学评价 Particle Enhanced Immunoturbidimetric Homocyteine Cardiovascular disease Evaluation test of methodology
  • 相关文献

参考文献8

  • 1Ozkan Y, Ozkan E, Simsek B. Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. IntJ Cardiol 2002;82(3):269-77.
  • 2Rasmussen K, Mller J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Clin Chem 1999;45(10):1850-5.
  • 3Brosnan JT,Jacobs RL,Stead LM,etal. Methylation demand: a key determinant of homocysteine metabolism. Acta Biochim Pol,2004,51 (2):405-413.
  • 4Mato JM,Alvarez L, Ortiz P, et al. S-adenosylmethionine synthesis: molecular mechanisrns and clinical implications. Pharmacol Ther, 1997,73(3):265-280.
  • 5Ueland PM, Refsum H. Plasma homoeysteine, a risk faetor for vascular disease : Plasma levels in health, disease, and drug therapy. J Lab Clin Med,1989,114(5): 473-501.
  • 6Amores-S d nchez MI, Medina MA. Method for the determination of Plasma total homocysteine. Clin Chem Lab Med 2000; 38(3):199-204.
  • 7Dou C, Xia D, Zhang L, Chen X, Flores P, Datta A, Yuan C. Development of a novel enzymatic cycling assay for total homocysteine. Clin Chem 2005,51(10): 1987-9.
  • 8高静,董振南,田亚平.循环酶法测定血清同型半胱氨酸的临床应用研究[J].中华检验医学杂志,2006,29(3):199-202. 被引量:42

二级参考文献10

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部